Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

BACKGROUND: Patients with COVID-19 pneumonia have an excess of inflammation and increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine whether anakinra, a recombinant human IL-1 receptor antagonist, could improve outcomes in patients in hospital with mild-to-mode...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825875/
https://www.ncbi.nlm.nih.gov/pubmed/33493450
http://dx.doi.org/10.1016/S2213-2600(20)30556-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825875/
https://www.ncbi.nlm.nih.gov/pubmed/33493450
http://dx.doi.org/10.1016/S2213-2600(20)30556-7

Ejemplares similares